p.74 抽出テキスト

CLINICAL STATEMENTS AND GUIDELINES

April 1, 2025 Circulation. 2025;151:e771–e862. DOI: 10.1161/CIR.0000000000001309 e844

plicated by cardiogenic shock: a report from the North-Rhine-Westphalia Surgical Myocardial Infarction Registry. J Am Heart Assoc. 2019;8:e012049. 12.	 Schomig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293:2865–2872. 13.	 Gierlotka M, Gasior M, Wilczek K, et al. Reperfusion by primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a prospective national observational study [PL-ACS]). Am J Cardiol. 2011;107:501– 508. 14.	 Ndrepepa G, Kastrati A, Mehilli J, et al. Mechanical reperfusion and longterm mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. JAMA. 2009;301:487–488. 15.	 Bouisset F, Gerbaud E, Bataille V, et al. Percutaneous myocardial revascularization in late-presenting patients with STEMI. J Am Coll Cardiol. 2021;78:1291–1305. 16.	 Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395– 2407. 17.	 Steg PG, Thuaire C, Himbert D, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J. 2004;25:2187– 2194. 18.	 Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18–e114. 19.	 Shen YC, Krumholz H, Hsia RY. Association of cardiac care regionalization with access, treatment, and mortality among patients with ST-segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2021;14:e007195. 20.	 Jollis JG, Al-Khalidi HR, Roettig ML, et al. Impact of regionalization of STsegment-elevation myocardial infarction care on treatment times and outcomes for emergency medical services-transported patients presenting to hospitals with percutaneous coronary intervention: Mission: Lifeline Accelerator-2. Circulation. 2018;137:376–387. 21.	 Jollis JG, Al-Khalidi HR, Roettig ML, et al. Impact of regionalization of ST-segment-elevation myocardial infarction care on treatment times and outcomes for emergency medical services: transported patients presenting to hospitals with percutaneous coronary intervention. Circulation. 2018;137:376–387. 22.	 Krumholz H, Herrin, J, Miller LW, et al. Improvements in door-to-balloon time in the United States, 2005 to 2010. Circulation. 2011;124:1038–1045. 23.	 Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155– 2165. 24.	 Jhand A, Atti V, Gwon Y, et al. Meta-analysis of transradial vs transfemoral access for percutaneous coronary intervention in patients with ST elevation myocardial infarction. Am J Cardiol. 2021;141:23–30. 25.	 Volz S, Angeras O, Koul S, et al. Radial versus femoral access in patients with acute coronary syndrome undergoing invasive management: a prespecified subgroup analysis from VALIDATE-SWEDEHEART. Eur Heart J Acute Cardiovasc Care. 2019;8:510–519. 26.	 Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190–192. 27.	 Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and longterm survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295:2511–2515. 28.	 Smilowitz NR, Alviar CL, Katz SD, Hochman JS. Coronary artery bypass grafting versus percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock. Am Heart J. 2020;226:255–263. 29.	 Hochman JS, Reynolds HR, Dzavik V, et al. Long-term effects of percutane-

ous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. Circulation. 2011;124:2320– 2328. 5.2.2. Urgent CABG Surgery 1.	 Pi Y, Roe MT, Holmes DN, et al. Utilization, characteristics, and in-hospital outcomes of coronary artery bypass grafting in patients with ST-segmentelevation myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. Circ Cardiovasc Qual Outcomes. 2017;10:e003490. 2.	 Grothusen C, Friedrich C, Loehr J, et al. Outcome of stable patients with

acute myocardial infarction and coronary artery bypass surgery within 48 hours: a single-center, retrospective experience. J Am Heart Assoc. 2017;6:e005498. 3.	 Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI

guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18–e114. 4.	 Patlolla SH, Kanwar A, Cheungpasitporn W, et al. Temporal trends, clinical characteristics, and outcomes of emergent coronary artery bypass grafting for acute myocardial infarction in the United States. J Am Heart Assoc. 2021;10:e020517. 5.	 Thielmann M, Wendt D, Slottosch I, et al. Coronary artery bypass graft sur-

gery in patients with acute coronary syndromes after primary percutaneous coronary intervention: a current report from the North-Rhine Westphalia Surgical Myocardial Infarction Registry. J Am Heart Assoc. 2021;10:e021182. 5.3. Reperfusion at Non–PCI-Capable Hospitals 1.	 Nielsen PH, Terkelsen CJ, Nielsen TT, et al. System delay and timing of intervention in acute myocardial infarction (from the Danish Acute Myocardial Infarction-2 [DANAMI-2] trial). Am J Cardiol. 2011;108:776–781. 2.	 Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003;108:1809–1814. 3.	 French WJ, Gunderson M, Travis D, et al. Emergency interhospital transfer of patients with ST-segment-elevation myocardial infarction: call 9-1-1-the American Heart Association Mission: Lifeline Program. J Am Heart Assoc. 2022;11:e026700. 4.	 Li K, Zhang B, Zheng B, et al. Reperfusion strategy of ST-elevation myocardial infarction: a meta-analysis of primary percutaneous coronary intervention and pharmaco-invasive therapy. Front Cardiovasc Med. 2022;9:813325. 5.	 Fazel R, Joseph TI, Sankardas MA, et al. Comparison of reperfusion strategies for ST-segment-elevation myocardial infarction: a multivariate network meta-analysis. J Am Heart Assoc. 2020;9:e015186. 6.	 Siontis KC, Barsness GW, Lennon RJ, et al. Pharmacoinvasive and primary percutaneous coronary intervention strategies in ST-elevation myocardial infarction (from the Mayo Clinic STEMI Network). Am J Cardiol. 2016;117:1904–1910. 7.	 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2:349–360. 8.	 Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Lancet. 1986;1:397–402. 9.	 An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682. 10.	 Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368:1379– 1387. 11.	 Schomig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293:2865–2872. 12.	 Gierlotka M, Gasior M, Wilczek K, et al. Reperfusion by primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a prospective national observational study [PL-ACS]). Am J Cardiol. 2011;107:501– 508. 13.	 Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet. 1994;343:311–322. 14.	 Huber K, Goldstein P, Danchin N, et al. Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks. Am Heart J. 2013;165:123–132. 15.	 Hsia RY, Shen YC. Percutaneous coronary intervention in the United States: risk factors for untimely access. Health Serv Res. 2016;51:592–609. 16.	 Nallamothu BK, Bates ER, Wang Y, et al. Driving times and distances to hospitals with percutaneous coronary intervention in the United States: implications for prehospital triage of patients with ST-elevation myocardial infarction. Circulation. 2006;113:1189–1195. 17.	 Horwitz JR, Nichols A, Nallamothu BK, et al. Expansion of invasive cardiac services in the United States. Circulation. 2013;128:803–810. 18.	 Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary

angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733–742.

Downloaded from http://ahajournals.org by on October 7, 2026